Sebi Bars Seven Entities for Stock Manipulation via Social Media Freezes 20 Crore Gains
UK Exports to US Plunge 25 as Trump Tariffs Reshape Trade Flows
Mortgage and Refinance Rates Continue Downward Trend on May 23 2026
BT Warns of Potential Increases in Smartphone Prices Citing Industry Pressures
Crude Oil Prices Retreat Amid Bearish Technical Pattern
FatPipe FATN Valuation Raised to 640 by Zacks SmallCap Research After Preliminary Q4 Business Update
Golden Entertainment GDEN Q4 2025 Earnings Steep Earnings Miss Amid Operational Challenges
FCRX Q1 2026 Earnings Narrow Miss on EPS Stable Note Performance
CRIS Q1 2026 Earnings Significant EPS Miss as Biotech Advances Pipeline Without Revenue
MGEE Q1 2026 Earnings EPS Surpasses Estimates on Strong Utility Performance
CME Q1 2026 Earnings EPS Slightly Misses Consensus as Shares Edge Higher
RPT Q1 2026 Earnings Significant EPS Miss Stock Declines
Skeena Resources Slips 35 as Bearish Pressure Tests Key Support Levels SKE
Rafael Holdings RFL Edges Higher Testing Key Resistance After 219 Gain
Kayne Anderson Energy Infrastructure Fund KYN Edges Lower Key Levels in Focus
MarketAxess MKTX Gains Ground as Trading Volume Stabilizes Key Resistance Ahead
enGene Holdings Inc ENGN Gains 349 as Stock Approaches Key Resistance
Navios Maritime Partners LP Provides Operational Update in Q1 2026 Earnings Call
UVV Q1 2026 Earnings EPS Misses Estimates Amid Challenging Market Conditions
Xenetic Biosciences XBIO Bounces 303 Holding Above Key Support
ATYR Q1 2026 Earnings NarrowerThanExpected Loss as Clinical Milestones Approach
ARI Q1 2026 Earnings Earnings Miss by 20 as Credit Costs Weigh Stock Edges Higher
TPG Mortgage Investment Trust Inc MITT Q1 2026 Earnings EPS Beats Estimates Amid Steady Portfolio Performance
GEO Q1 2026 Earnings EPS Surprises to the Upside Despite Flat Revenue Disclosure
THM Q1 2026 Earnings Modest Profit Reported Amid No Revenue and Market Pullback
QRHC Q1 2026 Earnings EPS Misses Estimates Stock Gains Despite Loss
TEVA Q1 2026 Earnings EPS Beats Estimates by 878 as Generic Drugmaker Posts Strong Quarter